Metabolic & Cardiometabolic
GLP-1 receptor agonists causes GI side effects via delayed gastric emptying (nausea, vomiting; rare gastroparesis)
In plain terms: Do GLP-1 drugs commonly cause stomach and GI side effects?
Part of: 💊 GLP-1 Drugs
Very commonly nausea, vomiting, diarrhea and constipation — usually mild/transient and tied to delayed gastric emptying — with a small but real increase in rarer events like gastroparesis and bowel obstruction.
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: All trials, pooled (Meta-analysis)
How the studies fall
The evidence (12)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Blundell 2018 · Diabetes Obes Metab | RCT | supports | high | Mechanism: semaglutide delayed first-hour gastric emptying in obesity (crossover), linking emptying delay to early satiety/nausea. |
| Xie 2025 · Diabetes Metab Syndr Obes | meta-analysis | supports | moderate | GLP-1/GIP co-agonists vs GLP-1RA: greater weight loss comes with higher GI adverse-event burden. |
| Newsome 2021 · N Engl J Med | RCT | supports | high | MASH trial: nausea 42% vs 11%, vomiting 15% vs 2%, constipation 22% vs 12% with semaglutide — reproduces GI signal across indications. |
| 2025 venue: Cureus · Cureus | observational | mixed | low | Case report/review: rare bowel obstruction with GLP-1RA; biologically plausible via motility slowing, but causality uncertain in case data. |
| Dahl 2021 · Diabetes Obes Metab | RCT | supports | moderate | Oral semaglutide delayed gastric emptying and improved postprandial glucose in T2D crossover — confirms emptying mechanism. |
| Wilding 2021 · N Engl J Med | RCT | supports | high | STEP-1: nausea 44%, diarrhea 32%, vomiting 25%, constipation 24% with semaglutide vs much lower placebo; mostly mild-moderate, transient. |
| Kristensen 2019 · Lancet Diabetes Endocrinol | meta-analysis | supports | high | CVOT MA notes GI AEs are the principal tolerability limitation of the class, exceeding placebo across trials. |
| Wharton 2022 · Diabetes Obes Metab | RCT | supports | high | STEP pooled GI tolerability: GI AEs concentrated during dose escalation, typically transient; modest extra weight loss in those affected. |
| Sodhi 2023 · JAMA | observational | supports | moderate | Pharmacoepi cohort (weight-loss use): GLP-1RA vs bupropion-naltrexone raised gastroparesis (HR 3.67, 1.15-11.90), bowel obstruction and pancreatitis. |
| Aronne 2025 · N Engl J Med | RCT | supports | high | SURMOUNT-5: GI AEs most common in both arms; mostly mild-moderate, consistent with mechanism, more frequent on tirzepatide. |
| de Mesquita 2023 · Int J Obes | meta-analysis | supports | moderate | Tirzepatide RCT MA: dose-dependent nausea/diarrhea/vomiting drive most discontinuations; class-consistent GI profile. |
| 2026 venue: Ann Intern Med · Ann Intern Med | observational | mixed | high | Comparative GI safety T2D cohort: GI event HRs near 1.0 between semaglutide/dulaglutide/tirzepatide — relative parity among agents (vs each other). |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.